Lack of acute effects of ascorbic acid on spirometry and airway responsiveness to histamine in subjects with asthma.
Sixteen adult subjects with asthma in a clinical steady state were studied. On day 1, after baseline spirometry, they underwent four histamine inhalation tests with functional recovery between each test. The provocative concentration causing a 20% fall in FEV1 (PC20) was obtained after each test. On days 2, 3, and 4, after baseline spirometry, active and placebo ascorbic acid (2 gm) was administered orally, double-blind, according to a 4.3.1 two-treatment crossover study design. One hour later, spirometry was performed, and PC20 was reassessed. We found no significant changes in FEV1 and FVC after ascorbic acid as compared with placebo administration. There was no difference between PC20 on days 2, 3, and 4 and by standardizing for the four PC20 results obtained on day 1. We conclude that ascorbic acid has no acute bronchodilator effect and does not alter bronchial responsiveness to histamine in subjects with asthma.
D000328:Adult; D000403:Airway Resistance / Q000187:drug effects*; D001205:Ascorbic Acid / Q000494:pharmacology*; D001249:Asthma / Q000503:physiopathology*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006632:Histamine / Q000494:pharmacology*; D006801:Humans; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012129:Respiratory Function Tests
D006632:Histamine; D001205:Ascorbic Acid